Associated Papers
Allele, Diplotype, and Phenotype Frequency Distribution of CYP2B6, CYP2C19, and CYP2D6 in the Han Population in North China.
Luan Y et al.
The Journal of Molecular Diagnostics : Jmd, 2026
A functional ancestry-linked regulatory haplotype influences CYP2D6 expression.
McCoy M
The Pharmacogenomics Journal, 2026
Influence of CYP2D6, CYP2C19, and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients.
Thomas L et al.
Pharmaceuticals (basel, Switzerland), 2026
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Development and Validation of a Multigene Panel for Pharmacogenomics Testing Using Next-Generation Sequencing for Routine Clinical Practice.
Hongkaew Y et al.
Clinical and Translational Science, 2026
Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine-Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions.
de la Cruz CG et al.
Pharmaceutics, 2025
From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment.
Mendes Batista AF et al.
Journal of Clinical Pharmacology, 2025
Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management.
Jayathilaka NS et al.
Clinical Pharmacology in Drug Development, 2025
Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.
Shenoy PV et al.
Cancer Metastasis Reviews, 2025
Polymorphisms of the CYP2D6 gene and its relationship with Plasmodium vivax relapses after chloroquine-primaquine treatment in Turbo, Colombia.
Sierra-Cifuentes V et al.
Diagnostic Microbiology and Infectious Disease, 2025
Influence of CYP2D6, CYP3A, and ABCG2 Genetic Polymorphisms on Ibrutinib Disposition in Chinese Healthy Subjects.
Fu K et al.
Pharmaceuticals (basel, Switzerland), 2025
How CYP2D6 Polymorphism Modulates the Community-Wide Risk of Plasmodium vivax Infection: A Panel Study in Amazonian Brazil.
Puça MCSB et al.
The Journal of Infectious Diseases, 2025
The role of genetic polymorphisms on drug response in Alzheimer's disease: a systematic review.
Climacosa FMM et al.
Bmc Medical Genomics, 2025
CYP2D6 and CYP2E1 Gene Polymorphisms and Their Influence on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.
Gudur RA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2025
Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes.
Zeng W et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2025
Evaluation of a targeted next-generation sequencing-based CYP2D6 genotyping method compared with Sanger sequencing and multiplex ligation-dependent probe amplification.
Choi WK et al.
Laboratory Medicine, 2025
Influence of pharmacokinetics-related gene polymorphisms on plasma levels of clozapine and its metabolites in Japanese patients with schizophrenia.
Kinoshita S et al.
Pcn Reports : Psychiatry and Clinical Neurosciences, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Pharmacogenetic pilot study of CYP2D6 and CYP1A2 genes in Italian patients with non-dystrophic myotonia and myotonic dystrophy treated with mexiletine.
Brugnoni R et al.
Gene, 2025
Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.
Díaz-Villamarín X et al.
Journal of Personalized Medicine, 2025
Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian Amazon.
da Silva GS et al.
Scientific Reports, 2025
Contrastive sequence signatures between the both sides of a recombination spot reveal an adaptation at PPARD locus from standing variation for pleiotropy since out-of-Africa dispersal.
Shou W et al.
Bmc Genomics, 2025
Analgesic therapy failure in a COMT HPS/HPS diplotype carrier heterozygous for the CYP2D6 *4 allele with fibromyalgia-a case report.
Bollinger A et al.
Pain Reports, 2025
CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer.
Xue C et al.
Bmc Cancer, 2025
The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's disease.
Kim TE et al.
The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.
Nahid NA et al.
Clinical and Translational Science, 2025
PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes.
Tremmel R et al.
Nucleic Acids Research, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
StarTRAC-CYP2D6: a method for CYP2D6 allele-specific copy number determination using digital PCR.
Wang WY et al.
Frontiers in Pharmacology, 2025
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R et al.
Jama Network Open, 2024
Catalogue of Somatic Mutations in Cancer Database and Structural Modeling Analysis of CYP2D6 Mutations in Human Cancers.
Kuchinski K et al.
The Journal of Pharmacology and Experimental Therapeutics, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants.
Beunk L et al.
European Journal of Human Genetics : Ejhg, 2024
Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.
Zhang X et al.
Ebiomedicine, 2024
Afro-Latin American Pharmacogenetics of CYP2D6, CYP2C9, and CYP2C19 in Dominicans: A Study from the RIBEF-CEIBA Consortium.
Guevara M et al.
Pharmaceutics, 2024
Association Between CYP2D7 and TCF20 Polymorphisms and Coronary Heart Disease.
Zhang W et al.
Cardiovascular Toxicology, 2024
Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report.
Sun C et al.
Bmc Pulmonary Medicine, 2024
Investigating the Correlation between Genotypes and Hepatic Protein Expression of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 Using Postmortem Tissue from a Danish Population.
Pedersen KW et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Molecular Mechanisms Underlying Single Nucleotide Polymorphism-Induced Reactivity Decrease in CYP2D6.
Becker D et al.
Journal of Chemical Information and Modeling, 2024
Establishing national reference materials for genetic testing of cytochrome P450.
Jia Z et al.
Pharmacogenetics and Genomics, 2024
Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
Puça MCSB et al.
The Journal of Antimicrobial Chemotherapy, 2024
The Frequency of CYP2D6 and CYP3A4/5 Genotypes and The Impact of Their Allele Translation and Phenoconversion-Predicted Enzyme Activity on Risperidone Pharmacokinetics in Saudi Children with Autism.
Shilbayeh SAR et al.
Biochemical Genetics, 2024
The potential Role of CYP2D6*10(c.100 C>T) Gene Polymorphism in Kidney Injury of Patients with Hypertension Complicated with Non-Elevated Cystatin C.
Jiang Y et al.
Cardiovascular Toxicology, 2024